A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study

OBJECTIVE: To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. METHODS: Patients (pts) with FIGO (1998) Stage IIIA/IIIC with positive c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol
Autors principals: McMeekin, D Scott, Sill, Michael W, Walker, Joan L, Moore, Kathleen N, Waggoner, Steven E, Thaker, Premal H, Rizack, Tina, Hoffman, James S, Fracasso, Paula M
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643744/
https://ncbi.nlm.nih.gov/pubmed/25958319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.04.038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars